At Idera, we’re passionate about what matters most – helping patients and their families. It’s what motivates us every day, and it’s why we’re laser-focused on developing tilsotolimod for those patients in need of new treatment options.
Idera is a clinical-stage biotechnology company focused on taking the next step in immuno-oncology therapies. We designed and are developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Our commitment is to bring breakthrough therapies to patients who need them most by acquiring, developing, and commercializing treatments for rare cancers and other rare diseases.